Catalio Capital Management
New York · 2 people tracked
Find your way into Catalio Capital Management
5,545 people in our graph share verified history with the Catalio Capital Management team — schools, employers, funds. One of them is your warm intro.
.jpg)
Investment thesis
Catalio is a software platform that uses AI to automatically extract and document business logic from legacy and modern systems, creating living specifications that stay current as software evolves.
Source: firm website, verified Aug 6, 2026.
Team · 2 people
from public directories
What they invest in
from 31 of 32 portfolio companiesBiotech ×23Healthtech ×18Medical Devices ×10AI & Machine Learning ×8Digital Health ×7Deep Tech ×2Wellness & Fitness ×2Advanced Manufacturing ×1
HQs:United States×25Switzerland×1
Investments · 32 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 52024 · 32023 · 42022 · 420 dated
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+7 more
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesJeito CapitalLongitude CapitalNovo Holdings+5 more
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)inThomas Miller(Founder)inNeil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)inMichael Secora(Chief Financial Officer and Chief Corporate Development Officer)in
Co-investorsAbingworthAscenta CapitalAlumni VenturesCatalio Capital Management, LPCoatue ManagementEisai Innovation, Inc.+4 more
Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space.
BiotechHealthtechMedical Devices
Co-investorsArboretum VenturesMaverick Ventures IsraelVisionary VenturesJohnson & Johnson Innovation – JJDCLifeSci Venture PartnersSequoia Capital+1 more
Spiral Therapeutics is a clinical-stage pharmaceutical company developing therapies for balance disorders and hearing loss using its Minimally Invasive Cochlear System (MICS) drug delivery platform.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Hugo Peris(Founder & CEO)inEugene de Juan(Executive Officer, Director)Lawrence Fritz(Director)
BoardWARREN THALER(Director)JEAN-FREDERIC PAULSEN(Director)Guy Nohra(Director)in
Co-investorsAlta PartnersEsperante Ventures
Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Max Mumbach(Founding Scientist, Target Discovery)inJeffrey Verboon(Founding Scientist, Computational Biology)inAnsu Satpathy(Founder)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)Howard Chang(Co-founder)in
Co-investors8VCAndreessen HorowitzArtis VenturesGlobal BioAccess FundHAWKTAILPfizer Venture Investments+6 more
Character Bio is a patient-driven therapeutics company that combines genomics, longitudinal clinical and imaging data, and machine learning to identify genetic drivers of disease progression and develop new treatments, with a focus on polygenic diseases.
AI & Machine LearningBiotechDigital HealthJersey City, US
Cheng Zhang(CEO, Co-Founder)inMarcel van der Brug(Scientific Advisor, Co-Founder)inNick Johnson(Technology Advisor, Co-Founder)inDaniel Elgort(Chief Data and Analytics Officer)inLaura Carter(Chief Scientific Officer)inRobert Kim(Chief Medical Officer)in
Co-investorsaMoonSanofi VenturesInnovation EndeavorsLuma GroupCantos VenturesCatalio Capital Management, LP+3 more
BiotechJersey City, US
Henry Rath(Executive Officer)Susan Orr(Executive Officer)inClarke Atwell(Executive Officer, Director)Stephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)
Co-investorsNovo HoldingsSamsara BioCapitalSofinnova Ventures
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.
BiotechHealthtechCambridge, US
Co-investorsCatalio Capital Management, LPCure VenturesVivo CapitalNovo HoldingsThird Rock Ventures
Cortex Robot builds datasets for embodied AI and robotics, including egocentric video data from real workplaces and robot trajectories for training physical intelligence systems.
Advanced ManufacturingAI & Machine LearningData & InfrastructureRoboticsSan Francisco, US
Lucas Ngoo(Founder)in
Co-investorsTranspose Platform ManagementY CombinatorGV (Google Ventures)Lux Capital
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)Paula Soteropoulos(Director)Stephen Knight(Director)
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+7 more
Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.
BiotechCambridge, US
Gabriel Kwong(Executive Officer)Sirshendu Roopom Banerjee(Executive Officer)
BoardTheresia Guow(Director)Amy Schulman(Director)inStan Lapidus(Director)
Co-investorsGreatPoint VenturesAcrew CapitalAspect VenturesDns CapitalNew Leaf Venture PartnersPolaris Partners+2 more
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.
BiotechDigital Health
Alvin Shih(CEO)inAlbert M. Kim(Chief Medical Officer)in
Co-investorsAN Venture PartnersRA CapitalSanofi VenturesSV Health Investors
BiotechBoston, US
Pavan Cheruvu(Director)Alvin Shih(Executive Officer, Director)inKomal Joshi(Executive Officer)inPieter Boelhouwer(Director)David-Alexandre C. Gros(Executive Officer, Director)
BoardCharles Dunn(Director)
Co-investorsRA CapitalSV Health Investors
Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.
AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US
Aaron Hurst(Founder)in
Co-investorsVoyager CapitalAlly Bridge GroupAmed VenturesAscension VenturesBain Capital Life SciencesDelos Capital+2 more
Insightec develops Exablate Neuro, an MRI-guided focused ultrasound platform that treats Essential Tremor and tremor-dominant Parkinson's Disease through an incision-free outpatient procedure.
HealthtechMedical DevicesTirat Carmel
Roni Karie(Vice President - Finance)Shirel Aroshase(Vice President - Human Resources)inEyal Zadicario(General Manager)inMenashe Frank(Vice President - Legal)inJun (Jim) Tao(Chief Operating Officer)inMaurice R. Ferre(Chairman and Chief Executive Officer)in
Co-investorsCatalio Capital Management, LPExigent CapitalGEOCJazzya InvestmentsKoch Disruptive TechnologiesKrillion Ventures+7 more
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundBiotechnology Value Fund+2 more
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.
BiotechHealthtechAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)inIvan Cheung(Chief Executive Officer)inLeena Gandhi(Chief Medical Officer)inTatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)
Co-investorsCatalio Capital Management, LPMPM BioImpactSanofi VenturesInvusLeaps by BayerSixty Degree Capital
Noetik builds AI models to identify cancer patients most likely to respond to treatments and to discover new oncology drug targets.
AI & Machine LearningBiotechHealthtechSouth San Francisco, US
Jacob Rinaldi(Executive Officer, Director, Promoter)inRonald Alfa(Executive Officer, Director, Promoter)Ron Alfa, MD, PhD(Founder)in
BoardJames Hardiman(Director)inAmy Schulman(Director)in
Co-investors11.2 CapitalBreakout VenturesLinearis VenturesNorth South VenturesDCVC (Data Collective)EPIC VENTURES+2 more
Tukwila, US
Robert Andrade(Executive Officer, Director, Promoter)Maurice J. Costantini(Executive Officer, Director, Promoter)
Co-investors8VCAndreessen HorowitzSV Angel
BiotechSouth San Francisco, US
Watson Debi(Director)Anne Rubin(Executive Officer, Director)Kirsten Angela Macfarlane(Executive Officer, Director, Promoter)Cameron Wheeler(Director)Randall Olson(Director)Robert Jackson(Director)
Co-investorsCatalio Capital Management, LPBraidwellDeerfield Management CompanyGV (Google Ventures)Johnson & Johnson Innovation – JJDC
Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.
BiotechHealthtechMedical DevicesRedwood City, US
Irv Weissman(Cofounder, Scientific Advisor, Board Director)Ravi Majeti(Cofounder, Scientific Advisor, Board Observer)Amira Barkal(Principal Founder, Scientific Advisor, Board Director)inRoy Maute(Cofounder & Chief Executive Officer)in
BoardJacob Vogelstein(Director)Steven Gillis(Director)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPAlexandria
ProSomnus offers oral appliance devices for treating obstructive sleep apnea and snoring, positioned as an alternative to CPAP machines.
Digital HealthHealthtechMedical DevicesWellness & FitnessPleasanton, US
Leonard Liptak(Executive Officer, Director)Sung Kim(Executive Officer)Jason Orchard(Director)Steven Pacelli(Director)Heather Rider(Director)Laing Rikkers(Executive Officer, Director)
Co-investorsCatalio Capital Management, LPSpring Mountain Capital
Ratio Therapeutics develops radiopharmaceuticals for oncology, working on targeted radiochemistry, discovery, and preclinical and clinical development.
BiotechHealthtechMedical DevicesBoston, US
John Babich(Director, President & Chief Scientific Officer)inJack Hoppin(Chairman & Chief Executive Officer)inWilliam Cupelo(Chief Business Officer)Matthias Friebe(Chief Technology Officer)inScott Holbrook(Chief Commercial and Manufacturing Officer)inJacob Hesterman(Chief Data Officer)in
Rhapsogen is developing a precision biologic therapy aimed at treating autoimmune diseases, focused on efficacy, safety, and durability.
BiotechHealthtech
Co-investorsCatalio Capital Management, LP
HealthtechCambridge, US
Rahul Dhanda(Executive Officer, Director)James Collins(Director)David Walt(Director)in
BoardIssi Rozen(Director)in
Co-investorsCatalio Capital Management, LPIllumina VenturesGood VenturesGV (Google Ventures)Northpond VenturesNovalis LifeSciences
Somethings connects teenagers with peer mentorship support to address gaps in mental health access in the United States.
Digital HealthHealthtechMental HealthWellness & Fitness
Patrick Gilligan(Founder & CEO)in
Co-investorsCoalition OperatorsTau VenturesGaingelsGeneral CatalystMVP VenturesPlug and Play Ventures+1 more
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)Michelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+8 more
Syndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's.
AI & Machine LearningBiotechDigital Health
Co-investorsEvolution VC PartnersTenmilePalo Santo
Visby offers an FDA-authorized at-home PCR test kit for women's sexual health that detects chlamydia, gonorrhea, and trichomoniasis from a single swab, delivering private results via a mobile app in about 30 minutes with included same-day telehealth for positive results.
ConsumerDigital HealthFemTechHealthtechMedical DevicesTokyo, US
Adam de la Zerda(Founder)in
Co-investors+ND Capital1809 CapitalAmplify PartnersArtiman VenturesG Vision CapitalKhosla Ventures+5 more
BiotechHealthtechDurham, US
Xiling Shen(Executive Officer, Director, Promoter)David Shiaowen(Director)William Roy Smythe(Executive Officer, Director)
BoardAlaa Halawa(Director)John de Koning(Director)
Co-investorsAlexandriaAlix VenturesEQT Life SciencesFelicis VenturesMC Healthcare VenturesMubadala Capital+2 more
Exits · 1
IPOs and acquisitions across the tracked portfolioAvalyn Pharma IncNASDAQ: AVLN
Portfolio news
latest coverage across their companies
Ensoma · fiercebiotech.com · Aug 7, 2026
Claris Biotherapeutics · finsmes.com · Aug 3, 2026
Ratio Therapeutics · finsmes.com · Aug 3, 2026
Cortex AI · roboticsandautomationnews.com · Jul 17, 2026
Iambic · geekwire.com · Jul 13, 2026
Alentis · biopharminternational.com · Jun 29, 2026
Clasp Therapeutics · catalyticagency.com · Jun 18, 2026
Frequently asked questions
- What sectors does Catalio Capital Management focus on?
- Catalio Capital Management focuses on Developer Tools, Enterprise Software.
- Where is Catalio Capital Management located?
- Catalio Capital Management is headquartered in New York, US.
Images
Co-investors · 12
Catalio is a New York-based investment firm focused on innovative healthcare, investing across the full lifecycle through private, public, and credit markets.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
What If Ventures is a venture capital firm investing in transformative technology, with a focus on healthcare/mental health and defense technology.
Presight Capital is the international venture fund of entrepreneur Christian Angermayer, operating as a registered investment adviser that can invest across public and private markets with checks from $500K to $100M+ throughout a company's entire lifecycle from seed to post-IPO. The fund is backed by prominent hedge fund managers and billionaire angels rather than traditional institutional investors, and focuses heavily on controversial frontier science like psychedelics, brain-computer interfaces, and life extension alongside transformative infrastructure bets in undercapitalized global markets.
Dimension is a multistage investment firm that partners with companies working at the intersection of science and compute.
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Inveready is a Spanish alternative investment firm founded in 2008, offering investment solutions and wealth management services across the small and mid-market segment in Spain.
Firms observed investing alongside Catalio Capital Management, from public investor directories. Shared companies are the overlap with Catalio Capital Management's recorded portfolio.
Similar investors
Accel is a venture capital firm that partners with exceptional teams, positioning itself as a first partner to founders globally.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.
Blumberg Capital is an early-stage venture capital firm founded in 1991, with offices in Miami, San Francisco, New York and Tel Aviv.
CRV is a venture capital firm that backs founders at the seed and Series A stages, focusing on those with deep conviction and unique insights.
Cornerstone Venture Partners is an early-stage venture capital firm that invests in B2B technology companies across the US and Israel.